Why the WADA appeal into Jannik Sinner doping case cuts to the heart of anti-doping priorities

At the heart of the doping case against Jannik Sinner, the top-ranked men’s tennis player in the world, is an existential debate about the policing of performance-enhancing drugs (PEDs) in sport.

Are the primary goals to catch cheats and prevent athletes from gaining unfair advantages over their peers? What happens when the enforcers of the World Anti-Doping Code see violations but uniformly agree that an athlete didn’t gain or chase such an edge?

Numerous athletes have found themselves in the middle of this debate and now the two-time Grand Slam champion is having his turn, with one anti-doping agency taking another anti-doping agency to the Court of Arbitration for Sport (CAS).

An apology to anyone with a sensitivity to the alphabet soup of sports bureaucracy.

The World Anti-Doping Agency (WADA) appealed a ruling from an independent panel convened by the International Tennis Integrity Agency (ITIA), which found that the 23-year-old bore “no fault or negligence” after twice testing positive for clostebol, an anabolic steroid on the WADA prohibited substances list. The panel still found that he had committed two anti-doping violations.

WADA said in a statement that it is not seeking for any of Sinner’s results to be disqualified, aside from his run to the semifinals at the BNP Paribas Open, held at Indian Wells, Calif. (Those results were already disqualified in the decision shared by the ITIA).

It is contesting the dismissal of any blame attributable to Sinner, which, it says, “was not correct under the applicable rules”.

WADA therefore accepts the final ruling that Sinner did not intentionally dope, but is still making a point about its own credibility by seeking to change the terms of that ruling.

Sinner, who recently won the U.S. Open, could be banned from tennis for between one and two years if WADA prevails.

Sinner was informed of his positive tests in late March. The ITIA said he tested positive for clostebol on March 10, at the BNP Paribas Open in Indian Wells, Calif., and again on March 18, between that tournament and the Miami Open. The results carried mandatory provisional suspensions, which Sinner appealed.

At each appeal, and in a final hearing on Aug. 15, three separate independent tribunals convened by the ITIA and conducted by Sport Resolutions, an arbitration company, accepted the Italian world No. 1’s explanation for the positive tests. His physiotherapist, Umberto Ferrara, had brought Trofodermin, an over-the-counter healing spray containing clostebol, to Indian Wells. His physiotherapist, Giacomo Naldi, cut his hand and used the spray on that cut. Naldi then conducted massages on Sinner, which led to contamination with the substance on Naldi’s skin getting to Sinner’s skin.

GO DEEPER

Jannik Sinner built the team that made him world No. 1. Then he blew it up

Those tribunal decisions meant that Sinner first avoided the two provisional suspensions, and then, in the final hearing, a “period of ineligibility”, which would have been a dreaded, reputation-destroying ban. The first two successful appeals also meant that his case remained private until that final hearing, under ITIA protocol.

At the final hearing, the independent tribunal ruled that Sinner was not at fault for the positive tests. It said he received no advantage from clostebol, a notorious and antiquated anabolic steroid that East Germany used as part of state-sponsored doping programs in the 1970s and 1980s.

“Even if the administration had been intentional, the minute amounts likely to have been administered would not have had any relevant doping, or performance enhancing, effect upon the player,” said Professor David Cowan, a member of the tribunal who explained the ruling.

Still, since the clostebol was in his system, Sinner was found to have committed two anti-doping violations, for which the ITIA stripped him of his ranking points, prize money and results from Indian Wells. But it did not seek a suspension.

After six months of playing under a secret cloud, Sinner won the U.S. Open, the first tournament after the ITIA publicized the case and final ruling.

But three weeks later, on Saturday, WADA publicized its appeal against that ruling. The case now goes to CAS, generally the final arbiter of sports doping litigation.

Jannik Sinner is currently playing in Beijing, at the China Open. (Lintao Zhang / Getty Images)

Sinner is none too pleased. In a statement issued that Saturday, Sinner noted that there he had already gone through three separate hearings that confirmed he hadn’t intentionally broken the rules or competed unfairly.

“I understand these things need to be thoroughly investigated to maintain the integrity of the sport we all love,” he said. “However, it is difficult to see what will be gained by asking a different set of three judges to look at the same facts and documentation all over again.”

Sinner and WADA now find themselves in difficult territory. Ever since the ITIA’s announcement, Sinner has indirectly faced criticism — some of it more vituperative than verifiable — over perceptions of preferential treatment. Tennis is a sport of double standards, from better court allocations and higher appearance fees for higher-ranked players, to a keener ear from tennis authorities on the biggest issues in the sport. Sinner, as world No. 1, has more powerful and more readily available legal resources than most tennis players would in a similar situation.

While in other anti-doping cases, players have been provisionally suspended for many months while under investigation, it remains that the so-called silence over his case was not an element of preferential treatment, and instead adherence to the ITIA’s process for investigation.

Other Italian tennis players who have tested positive for the same substance as Sinner have been suspended and found at fault. Stefano Battaglino, another Italian tennis player, received a four-year ban in 2023. Battaglino failed to prove that his testing positive for clostebol was inadvertent after it was detected during a random drug test at an ITF event in Tunisia.

Jannik Sinner lost to Carlos Alcaraz in the semifinals at Indian Wells, where the first positive test was recorded. (Matthew Stockman / Getty Images)

This is one of the most complicated factors. Italy has a widespread and readily acknowledged issue with athletes testing positive for clostebol, because it is freely sold in the country as an ingredient in healing products — including the Trofodermin that Ferrara brought to Indian Wells. WADA has stated that around half the cases of positive clostebol tests come from the country.

WADA, meanwhile, is dealing with the aftermath of its decision not to investigate 23 Chinese swimmers who tested positive for the same heart drug seven months before the 2021 Tokyo Olympics. The swimmers were allowed to compete, and several of the athletes went on to win medals. In its statement on the case, issued in April 2024 after what it called, “Some misleading and potentially defamatory media coverage,” the agency said that it “was not in a position to disprove the possibility that contamination was the source” of the positive tests.

Travis Tygart, the leader of the U.S. Anti-Doping Agency (USADA) and a key figure in the cases of Lance Armstrong in cycling and Alberto Salazar in track, on Saturday tied their situations to WADA’s decision on Sinner.

“It’s unimaginable that WADA leaders would appeal this case when the rules were clearly followed by tennis yet do nothing when China swept 23 positive tests under the carpet that indisputably violated the rules,” Tygart said.

“As athletes are held to high standards by anti-doping authorities, it’s high time for WADA decision makers to also be.”

WADA responded to that statement by criticizing Tygart. “It is strange for Mr. Tygart to comment on a case when he is not involved, has not reviewed the file and does not have all the facts to hand. It is equally strange he would then compare it to a completely unrelated case in which he was also not involved and does not have the facts to hand,” said James Fitzgerald, a WADA spokesperson. “It might be more productive for Mr. Tygart to spend his time working on the problems in U.S. anti-doping rather than constantly commenting on what is going on elsewhere in the world.”

WADA acknowledges that the detection of clostebol has been greatly enhanced in recent years by advances in technology that make it possible to detect lower concentrations.

That has helped catch some instances of doping, especially when it comes to hard-to-detect new substances. But it has also led to capturing innocent athletes who, judging by the levels of a given substance detected, are not doping — at least not with the substance that triggers a positive test.

WADA’s rules, in this case, appear to still be catching up with its testing advances, creating an imbalance between science and administration as athletes see their careers and reputations at stake.

(Top photo: Lintao Zhang / Getty Images)